Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer

被引：0

作者：

Gajria, D. ^{[1
]}

King, T. ^{[1
]}

Pannu, H. ^{[1
]}

Sakr, R. ^{[1
]}

Modi, S. ^{[1
]}

Drullinsky, P. ^{[1
]}

Syldor, A. ^{[1
]}

Path, S. ^{[1
]}

Seidman, A. ^{[1
]}

Norton, L. ^{[1
]}

Rosen, N. ^{[1
]}

Hudis, C. ^{[1
]}

Chandarlapaty, S. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/0008-5472.SABCS12-P5-18-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-18-04

引用

页数：1

共 50 条

[41] Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR [J].

Gordon, Michael A. ;

D'Amato, Nicholas ;

Gu, Haihua ;

Wong, Darren ;

Elias, Anthony ;

Richer, Jennifer K. .

CANCER RESEARCH, 2015, 75

[42] HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab [J].

Ithimakin, Suthinee ;

Day, Kathleen C. ;

Malik, Fayaz ;

Zen, Qin ;

Dawsey, Scott J. ;

Bersano-Begey, Tom F. ;

Quraishi, Ahmed A. ;

Ignatoski, Kathleen Woods ;

Daignault, Stephanie ;

Davis, April ;

Hall, Christopher L. ;

Palanisamy, Nallasivam ;

Heath, Amber N. ;

Tawakkol, Nader ;

Luther, Tahra K. ;

Clouthier, Shawn G. ;

Chadwick, Whitney A. ;

Day, Mark L. ;

Kleer, Celina G. ;

Thomas, Dafydd G. ;

Hayes, Daniel F. ;

Korkaya, Hasan ;

Wicha, Max S. .

CANCER RESEARCH, 2013, 73 (05) :1635-1645

[43] Targeting HER2 heterogeneity in breast cancer [J].

Hamilton, Erika ;

Shastry, Mythili ;

Shiller, S. Michelle ;

Ren, Rongqin .

CANCER TREATMENT REVIEWS, 2021, 100

[44] Targeting HER2/3 in Breast Cancer [J].

Hepner A. ;

Modi S. ;

Jhaveri K. .

Current Breast Cancer Reports, 2017, 9 (2) :61-69

[45] Targeting HER2 beyond breast cancer [J].

Bhatnagar, Sanchita ;

Tushir-Singh, Jogender .

MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (03)

[46] Targeting HER2 for the Treatment of Breast Cancer [J].

Rimawi, Mothaffar F. ;

Schiff, Rachel ;

Osborne, C. Kent .

ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 :111-128

[47] HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab [J].

Maiik, Fayaz ;

Ithimakin, Suthinee ;

Day, Kathleen ;

Ignatoski, Kathy ;

Zen, Qin ;

Thomas, Dafydd ;

Bersano, Tom ;

Dawsey, Scott ;

Hall, Christopher ;

Davis, April ;

Quraishi, Ahmed A. ;

Tawakkol, Nader ;

Clouthier, Shawn G. ;

Day, Mark ;

Hayes, Daniel F. ;

Korkaya, Hasan ;

Wicha, Max S. .

CANCER RESEARCH, 2012, 72

[48] Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer [J].

Lion, Maeva ;

Harle, Alexandre ;

Salleron, Julia ;

Ramacci, Carole ;

Campone, Mario ;

Merlin, Jean-Louis .

ONCOLOGY LETTERS, 2016, 12 (03) :2028-2032

[49] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY [J].

Gullo, G. ;

Bettio, D. ;

Zuradelli, M. ;

Giordano, L. ;

Masci, G. ;

Bareggi, C. ;

Salvini, P. ;

Venci, A. ;

Santoro, A. .

ANNALS OF ONCOLOGY, 2010, 21 :101-101

[50] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer [J].

Elisa Van Raemdonck ;

G. Floris ;

P. Berteloot ;

A. Laenen ;

I. Vergote ;

H. Wildiers ;

K. Punie ;

P. Neven .

Breast Cancer Research and Treatment, 2021, 185 :183-194

← 1 2 3 4 5 →